Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 15;24(3):299–306. doi: 10.1038/s41556-022-00852-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 4 — a, Increased risk of AML progression in MDS patients with low PUS7 expression (HR=102, n=100) evaluated in HSPC from a previously published study²⁹. b, Decreased overall patient survival (n=44, HR=3.1, 95% CI, 1.4-6.9) and c, increased risk of AML progression (n=38, HR=10.1, 95% CI, 1.2-88) in patients with reduced HSPC mTOG expression. Patients with −7/del(7q) were excluded from the analysis. p-values were calculated using log-rank test. d-e, PUS7 levels in primary MDS-HSPC. Low PUS7 mRNA expression (I quartile) is associated with decreased overall survival (HR = 2.4, 95% CI 1.14–5.04, n=50). p-values were calculated using log-rank test. f, mTOG levels are reduced in high risk MDS and secondary AML (sAML) HSPC. mTOG levels were quantified by RT-qPCR and normalized to mir16 levels. *p =0.0205; **p=0.0082 (one-way ANOVA with multiple comparison). n=30 LR, 15 HR and 11 AML individual patient samples, presented as mean ± SD. g, Pairwise correlation between mTOG and PAIP1 or PABPC1 mRNA levels in primary MDS-HSPC (n=50). Expression of each of the RNAs was quantified by ddPCR and normalized to miR16 (mTOG) or HPRT1 levels (PAIP1 and PABPC1). The shaded region in each graph represents the confidence interval.

Source data